Plain-English translation of NCT06259552 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage trial (Phase 1) testing a new medication called SPX-303, which is designed to work in two ways: it targets immune cells that cancer uses to hide, and it also activates the body's own immune system to fight the tumor. Researchers want to find the right dose of this treatment, understand how safe it is, and see if it can slow down cancer growth in people with advanced solid tumors who haven't had success with other available treatments.
Some advanced cancers learn to escape the body's immune system by activating special 'off switches' on immune cells. This medication is designed to block those off switches and reactivate the immune system to attack cancer, offering hope to patients who no longer respond to standard treatment options.
You likely qualify if…
You likely don't qualify if…
You will receive the medication as an intravenous infusion (IV drip) every 3 weeks. The trial has two main phases: first, researchers will gradually increase the dose in small groups of patients to find the safest dose, then expand to treat more patients at that dose level. You will have regular visits for blood tests, imaging scans to measure your tumors, heart monitoring, and checkups to track how you're tolerating the treatment and whether your cancer is responding.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
United States